Medical professionals are increasingly rejecting weight loss as the primary metric for obesity management, calling for a transition toward comprehensive, long-term clinical care. During the Novo Nordisk Southeast Asia Obesity Summit held in Makati on Saturday, a panel of experts from the Philippines, India, and Australia characterized obesity as a complex, chronic condition driven by a combination of genetic, environmental, and societal factors.
The shift in perspective comes as data highlights the scale of the crisis in Southeast Asia. According to the Epidemiological Burden and Cost of Obesity in the Philippines study, approximately 41 percent of Filipino adults, totaling 29 million individuals, are currently classified as obese or overweight.
Clinical leaders at the summit emphasized that the medical objective must evolve beyond simple mass reduction. Dr. Marjorie Ramos, head of the Section of Endocrinology at St. Luke’s Medical Center-Quezon City, noted that the primary clinical goal is to mitigate the systemic cardiometabolic complications associated with the disease.
Traditional interventions, including behavior-focused programs and restrictive dietary protocols, are increasingly viewed as insufficient for long-term health maintenance. Dr. Mark Mellor, an obesity and metabolic health specialist from Australia, observed that current care models in many regions remain overly focused on achieving specific weight targets rather than providing sustainable, lifelong support for patients.
The medical community is now moving away from the historical framing of obesity as a failure of willpower or a simple lifestyle choice. Dr. Mellor stated that the prevailing narrative has evolved to recognize the condition as a multifaceted disease requiring interventions that address biological, psychological, and social dimensions.
Regulatory and healthcare policy challenges often complicate the implementation of these long-term strategies across the Asia-Pacific region. Experts noted that fragmented healthcare systems frequently prioritize acute care over the longitudinal management required for chronic metabolic conditions, creating barriers to consistent patient monitoring.
These systemic hurdles require a fundamental restructuring of how metabolic health is delivered in clinical settings. Policymakers and health administrators are being urged to integrate obesity care into standard chronic disease frameworks to ensure equitable access to care.
Modern pharmacological approaches are playing an increasing role in this new management paradigm. Dr. Sanjay Kalra, an endocrinologist based in India, highlighted the utility of medications such as semaglutide in clinical practice.
New medications — such as semaglutide, a drug that regulates appetite — are not only effective in promoting weight loss but also provide significant cardiometabolic benefits and reduce the risk of heart disease and diabetes.
The integration of these therapies requires rigorous clinical oversight to ensure patient safety and efficacy. Dr. Ramos emphasized that pharmacological treatments must be administered under the direct supervision of qualified health professionals and integrated into broader lifestyle management plans.
The transition toward a chronic disease management model reflects a broader trend in internal medicine to prioritize physiological outcomes over aesthetic or weight-based metrics. By focusing on cardiometabolic stability, clinicians aim to reduce the long-term burden of comorbidities like type 2 diabetes and cardiovascular disease.
This approach necessitates a fundamental change in how healthcare systems allocate resources for metabolic health. Rather than relying on short-term interventions, providers are being encouraged to establish longitudinal care pathways that adapt to the evolving needs of patients with chronic metabolic dysregulation.
Future clinical efforts will likely focus on refining these long-term care strategies and improving patient access to evidence-based medical interventions. The medical community remains focused on standardizing these protocols to ensure that patients receive consistent, science-backed support throughout their clinical management plan.
